# LLM Judge Evaluation: tier1_004

## Overall: FAIL

### Scores:
- **Completion**: 1/2
- **Correctness**: 0/2
- **Tool Use**: 1/2
- **Total**: 2/6

### Reasoning:
Completion:
- The trace shows molecule_lookup succeeded and a descriptor workflow was submitted with object_status 0 and no started_at/completed_at timestamps. No follow-up polling or retrieval occurred. The “FINAL ANSWER” promises a later status check but provides no numerical results or interpretation. Therefore, the workflow was initiated but not completed and no results were presented.

Correctness:
- Because no computed descriptor values were returned, there is nothing to compare against literature. I still verified credible literature values for key properties (pKa, logP/logD, solubility, tPSA, MW, HBD/HBA, rotatable bonds) from DrugBank/PubChem and peer‑reviewed/PMC sources to establish expected ranges for psilocybin. However, with no agent values, error cannot be calculated, so correctness must be scored 0 by rubric.

Tool Use:
- The SMILES retrieved for psilocybin matches authoritative records (PubChem CID 10624), indicating correct molecule identification. A descriptors workflow was submitted with a sensible input. However, the agent did not poll, retrieve, or present results. Thus, tools were appropriate but the sequence was incomplete.

Additional context for the task (not part of scoring but relevant to CNS development):
- Key CNS-relevant descriptors for psilocybin include MW (~284 g/mol), tPSA (~85.8 Å²), logP predictions between −0.14 and 1.25, HBD/HBA (3/4), rotatable bonds (5), and pKa values for phosphate (≈1.3 and 6.5) and the dimethylamine (≈10.4), yielding a zwitterion typically bearing net −1 charge at physiological pH. These features imply poor passive BBB penetration; psilocybin acts as a prodrug for psilocin, which has lower tPSA (~39–41 Å²) and is BBB-permeable. ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))

### Feedback:
- You correctly resolved the psilocybin SMILES and initiated a descriptor workflow, but you stopped before polling and retrieving results. Always poll to completion and return a concise table of key descriptors (MW, tPSA, logP/logD7.4, pKa(s), HBD/HBA, rotatable bonds, fraction csp3, aromatic rings).
- Interpret the values for CNS developability (e.g., compare tPSA and logD7.4 to BBB benchmarks, note zwitterionic charge), and, for psilocybin specifically, explicitly discuss that psilocin is the BBB‑permeable active moiety.
- If computation is pending, provide interim literature values with citations and clearly label them as literature vs computed, then follow up with computed numbers once available.
- Literature validation: Because the agent produced no numerical descriptors, no error can be computed. I provide vetted literature values for reference.

- Property: pKa (psilocybin)
  1) Agent's computed value: none
  2) Literature value: phosphate pKa1 ≈ 1.3, pKa2 ≈ 6.5; tertiary amine pKa ≈ 10.4. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Psilocybin?utm_source=openai))
  3) Absolute error: N/A
  4) Percent error: N/A
  5) Score justification: No agent value to compare; by rubric, correctness = 0.

- Property: logP (psilocybin)
  1) Agent's computed value: none
  2) Literature value: predicted logP −0.14 (ChemAxon) to 1.25 (ALOGPS). ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))
  3) Absolute error: N/A
  4) Percent error: N/A
  5) Score justification: No agent value to compare; correctness = 0.

- Property: Aqueous solubility (psilocybin)
  1) Agent's computed value: none
  2) Literature value: water solubility ≈ 2.7 g/L (≈2.7 mg/mL). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8883979/?utm_source=openai))
  3) Absolute error: N/A
  4) Percent error: N/A
  5) Score justification: No agent value to compare; correctness = 0.

- Property: Topological polar surface area (tPSA; psilocybin)
  1) Agent's computed value: none
  2) Literature value: predicted tPSA ≈ 85.79 Å². ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))
  3) Absolute error: N/A
  4) Percent error: N/A
  5) Score justification: No agent value to compare; correctness = 0.

- Additional identifiers/descriptors for psilocybin (for CNS relevance)
  • Molecular weight: 284.25 g/mol; HBD/HBA: 3/4; rotatable bonds: 5; physiological charge often −1 at pH 7.4 (zwitterion). ([go.drugbank.com](https://go.drugbank.com/drugs/DB11664?utm_source=openai))

Context note: Psilocybin’s high polarity/charge profile implies poor BBB penetration; it is a prodrug converted to psilocin (psilocin pKa for amine ≈ 8.47 by NMR; tPSA ≈ 39–41 Å²; XlogP around 2), which is the CNS‑active species. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/6259355/?utm_source=openai))

### Web Search Citations:
1. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
2. [Psilocybin](https://en.wikipedia.org/wiki/Psilocybin?utm_source=openai)
3. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
4. [Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective? - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC8883979/?utm_source=openai)
5. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
6. [Psilocybin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB11664?utm_source=openai)
7. [Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy - PubMed](https://pubmed.ncbi.nlm.nih.gov/6259355/?utm_source=openai)

### Execution:
- **Tools**: submit_descriptors_workflow, molecule_lookup
- **Time**: 0.5 min

---
*Evaluated with openai/gpt-5*
